Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Coleman

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Translational Cancer Research|August 7, 2012
Normal tissue protection for improving radiotherapy: Where are the Gaps?Pataje G S Prasanna, Helen B Stone, Rosemary S Wong, et al.
Cancer|January 15, 1984
The effect of postoperative and primary radiation therapy on delivered dose of adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy in breast cancerJ F Levine, C N Coleman, R S Cox, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1996
Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20)C A Lawton, C N Coleman, J W Buzydlowski, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1996
Analysis of prostate and seminal vesicle motion: implications for treatment planningC J Beard, P Kijewski, M Bussière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapyK C Marcus, L A Kalish, C N Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiationP Mauch, N Tarbell, H Weinstein, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 1989
Alpha particle radio-immunotherapy: animal models and clinical prospectsR M Macklis, W D Kaplan, J L Ferrara, et al.
Cancer Research|February 15, 1991
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinomaB A Teicher, T S Herman, J Tanaka, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experienceD J Lee, T L Phillips, C N Coleman, et al.
Cancer|July 1, 1993
Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapyM Uematsu, N J Tarbell, B Silver, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Translational Cancer Research|August 7, 2012
Normal tissue protection for improving radiotherapy: Where are the Gaps?Pataje G S Prasanna, Helen B Stone, Rosemary S Wong, et al.
Cancer|January 15, 1984
The effect of postoperative and primary radiation therapy on delivered dose of adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy in breast cancerJ F Levine, C N Coleman, R S Cox, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1996
Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20)C A Lawton, C N Coleman, J W Buzydlowski, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1996
Analysis of prostate and seminal vesicle motion: implications for treatment planningC J Beard, P Kijewski, M Bussière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapyK C Marcus, L A Kalish, C N Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiationP Mauch, N Tarbell, H Weinstein, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 1989
Alpha particle radio-immunotherapy: animal models and clinical prospectsR M Macklis, W D Kaplan, J L Ferrara, et al.
Cancer Research|February 15, 1991
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinomaB A Teicher, T S Herman, J Tanaka, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experienceD J Lee, T L Phillips, C N Coleman, et al.
Cancer|July 1, 1993
Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapyM Uematsu, N J Tarbell, B Silver, et al.
Pageof 14